Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Recombinant human erythropoietin vs transfusions in the treatment of anemia of prematurity. A cost-benefit analysis.

Shireman TI, Hilsenrath PE, Strauss RG, Widness JA, Mutnick AH.

Arch Pediatr Adolesc Med. 1994 Jun;148(6):582-8.

PMID:
8193681
2.

A cost analysis comparing erythropoietin and red cell transfusions in the treatment of anemia of prematurity.

Fain J, Hilsenrath P, Widness JA, Strauss RG, Mutnick AH.

Transfusion. 1995 Nov-Dec;35(11):936-43.

PMID:
8604492
4.

Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study.

Meyer MP, Meyer JH, Commerford A, Hann FM, Sive AA, Moller G, Jacobs P, Malan AF.

Pediatrics. 1994 Jun;93(6 Pt 1):918-23.

PMID:
8190577
5.

Recombinant human erythropoietin in the treatment of anemia of prematurity.

Chen JY, Wu TS, Chanlai SP.

Am J Perinatol. 1995 Sep;12(5):314-8.

PMID:
8540930
6.

The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group.

Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G, Halliday HL, Versmold HT, Moriette G, Jorch G, et al.

N Engl J Med. 1994 Apr 28;330(17):1173-8.

7.

Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity.

Soubasi V, Kremenopoulos G, Diamanti E, Tsantali C, Sarafidis K, Tsakiris D.

J Pediatr. 1995 Aug;127(2):291-7.

PMID:
7636658
9.

Anaemia of prematurity. Epidemiology, management and costs.

Meyer MP.

Pharmacoeconomics. 1997 Oct;12(4):438-45. Review.

PMID:
10174310
10.

Is the use of recombinant human erythropoietin in anaemia of prematurity cost-effective?

Meyer MP, Haworth C, McNeill L.

S Afr Med J. 1996 Mar;86(3):251-3.

PMID:
8658295
11.
12.
13.

Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy.

Kavanagh BD, Fischer BA 4th, Segreti EM, Wheelock JB, Boardman C, Roseff SD, Cardinale RM, Benedict SH, Goram AL.

Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):435-41.

PMID:
11567818
14.
15.

Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants.

Schneider JK, Gardner DK, Cordero L.

Pharmacotherapy. 2008 Nov;28(11):1335-40. doi: 10.1592/phco.28.11.1335.

PMID:
18956993
16.

Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia.

Giannakopoulou C, Bolonaki I, Stiakaki E, Dimitriou H, Galanaki H, Hatzidaki E, Kalmanti M.

Pediatr Hematol Oncol. 1998 Jan-Feb;15(1):37-43.

PMID:
9509504
17.

[Prevention of neonatal anemia with recombinant human erythropoietin: a cost-benefit analysis].

Schefels J, Merz U, Hörnchen H.

Z Geburtshilfe Neonatol. 1999 Dec;203 Suppl 2:1-5. German.

PMID:
10612190
19.

Use of recombinant erythropoietin in treatment of the anemia of prematurity.

Halpérin DS.

Am J Pediatr Hematol Oncol. 1991 Fall;13(3):351-63. Review.

PMID:
1793163
20.

Score for neonatal acute physiology and phlebotomy blood loss predict erythrocyte transfusions in premature infants.

Kling PJ, Sullivan TM, Leftwich ME, Roe DJ.

Arch Pediatr Adolesc Med. 1997 Jan;151(1):27-31.

PMID:
9006525

Supplemental Content

Support Center